RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Mariana Gerschenson to HIV-Associated Lipodystrophy Syndrome

This is a "connection" page, showing publications Mariana Gerschenson has written about HIV-Associated Lipodystrophy Syndrome.
  1. Gojanovich GS, Shikuma CM, Milne C, Libutti DE, Chow DC, Gerschenson M. Subcutaneous Adipocyte Adenosine Triphosphate Levels in HIV Infected Patients. AIDS Res Hum Retroviruses. 2020 01; 36(1):75-82.
    View in: PubMed
    Score: 0.685
  2. Shikuma CM, Gangcuangco LM, Killebrew DA, Libutti DE, Chow DC, Nakamoto BK, Liang CY, Milne CI, Ndhlovu LC, Barbour JD, Shiramizu BT, Gerschenson M. The role of HIV and monocytes/macrophages in adipose tissue biology. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):151-9.
    View in: PubMed
    Score: 0.464
  3. McComsey GA, O'Riordan M, Choi J, Libutti D, Rowe D, Storer N, Harrill D, Gerschenson M. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther. 2012; 17(2):347-53.
    View in: PubMed
    Score: 0.396
  4. Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother. 2009 Jun; 63(6):1244-50.
    View in: PubMed
    Score: 0.331
  5. McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, Ganz J, Jasper J, Harrill D, Gerschenson M. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther. 2008; 13(5):715-22.
    View in: PubMed
    Score: 0.304
  6. Gerschenson M, Shiramizu B, LiButti DE, Shikuma CM. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther. 2005; 10 Suppl 2:M83-9.
    View in: PubMed
    Score: 0.247
  7. Day L, Shikuma C, Gerschenson M. Acetyl-L-carnitine for the treatment of HIV lipoatrophy. Ann N Y Acad Sci. 2004 Nov; 1033:139-46.
    View in: PubMed
    Score: 0.244
  8. Gerschenson M. Mitochondria and lipodystrophy: where are we now? Antivir Ther. 2003 Aug; 8(4):261-3.
    View in: PubMed
    Score: 0.224
  9. McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013 Feb 15; 207(4):604-11.
    View in: PubMed
    Score: 0.107
  10. Tungsiripat M, O'Riordan MA, Storer N, Harrill D, Ganz J, Libutti D, Gerschenson M, McComsey GA. Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials. 2009 Sep-Oct; 10(5):314-9.
    View in: PubMed
    Score: 0.085
  11. Shikuma CM, Gerschenson M, Chow D, Libutti DE, Willis JH, Murray J, Capaldi RA, Marusich M. Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status. AIDS Res Hum Retroviruses. 2008 Oct; 24(10):1255-62.
    View in: PubMed
    Score: 0.080
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support